A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM

Sponsor
The First Affiliated Hospital of Soochow University
Study ID
NCT05088330
Status
Unknown

Conditions

  • Newly Diagnosed Multiple Myeloma

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, single arm study to access the effect of treatment with D-VRD in patients with newly diagnosed standard risk multiple myeloma.

Key Dates

Start date
Dec 1, 2021
Status verified
Oct 2021
Primary completion
May 30, 2023
Completion
Dec 31, 2024

Study Design

Enrollment
76 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: D-VRD
    treatment with D-VRD in NDMM

Primary Outcome Measure

rate of minimal residual disease negativity [ Time Frame: end of 8 cycles ]

Related Studies